Updated data with lenvatinib and Pembrolizumab in 158 1st line advanced non-clear cell renal cancer #ikcs24 . 8 mnths extra FU. RR= 50% seems higher than sunitinib. 18 month mPFS and 80% 12 month OS also looks ⬆️, but randomised trials such as SAMETA and XL92/nivo remain important

Spring is Stunning in Chicago.

I’m thrilled to announce that National Cancer Institute renewed our designation as a Comprehensive Cancer Center for the high-impact work we do for cancer patients and the community. ow.ly/HUOc50R5Jut #NothingWillStopUs #WeAreNCIDesignated #UChiCancer50
Kunle Odunsi, MD

Excited to welcome those in the Chicago area to the next GU Rounds Ivy Room Chicago!

Jam packed agenda +dinner w/ exciting cross-disciplinary discussions in prostate, bladder, renal cancers.

Still a few spots left to sign up @ gurounds.com for this April 3 CME event

Thrilled on our lastest publication in European Urology Oncology!
ctDNA may revolutionize the way we choose treatment modalities for patients with bladder cancer.
Paving our way in adding the letter G-for genomic to TNM staging, adding another layer of clarity to our patients.

🚨Call for Abstracts! You can secure a sponsored seat at #KCRS24 by sharing your work:

➡️Basic/Translational Research
➡️Clinical Research
➡️Trials in Progress

Details: bit.ly/KCRS24Abstract…

Submit by May 6. Don't miss your chance!

OncoAlert

The UChicago Breast Cancer Program is excited organize a Stat of the Science Summit on March 21, 2024 in downtown Chicago. Please join us! #bcsm

A glorious end to Thursday in Chicago. This evening's sunset. #weather #ilwx #news #chicago

MODERN is now activated. Please help define a precision-based approach to adjuvant therapy in bladder cancer. Bladder Cancer Advocacy Network Uromigos Alliance for Clinical Trials in Oncology Alan Tan Stephanie Berg Jonathan Rosenberg MD Shilpa Gupta Andrea Apolo, M.D. SWOG Cancer Research Network ECOG-ACRIN Cancer Research Group Petros Grivas Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO DrTylerStewart

Big news for our #melanoma community today: lifileucel is finally FDA approved!

I think this is a paradigm shifting, 'first-of-many' approval in the field of cellular therapeutics for solid tumors. Much more to do, but for today, we celebrate!

ir.iovance.com/news-releases/…

Updated analysis showing ctDNA as potentially predictive and prognostic marker after cystectomy in muscle invasive bladder cancer. CtDNA clearance also looks important. New data on relapse rates in ctDNA-ve with be #EAU24 joaquim bellmunt European Urology

We are looking for a motivated PhD student for exciting spatial transcriptomics projects in urothelial cancer! Our lab has been involved in important clinical and translational molecular UC research in the past years. PM if you are interested to join!
xing.com/jobs/erlangen-…

Check out our poster at ASCO GU: collaboration UChicagoCancerCenter & Vanderbilt-Ingram Cancer Center (@KSchaffer17 & Brian Rini, MD) analyzing n=146 mCRPC pts who received SOC Lu177 (PLUVICTO).

💊Our cohort received fewer cycles of Lu177, higher rate of anemia (25% required RBC tx) & lower PS vs VISION

We are hiring a scientist (assistant professor) who will focus on #immunology and #bladdercancer McGill Dept of Surg Centre universitaire de santé McGill McGill University strong and supportive academic environment in the wonderful city of @montreal please apply or RT

mcgill.wd3.myworkdayjobs.com/en-US/McGill_C…

GO BLUE!! Finally a Big 10 win vs ‘Bama when it counts! What an incredible season, long awaited since my residency days 😁 Can’t imagine what Ann Arbor is like right now. One more to go!

Congratulations to Jing Chen, PhD and colleagues on publishing an excellent paper in
nature
demonstrating the action of dietary trans-vaccenic acid (TVA) in promoting effector CD8+ T cell function and anti-tumour immunity in vivo.
UChicagoCancerCenter
ow.ly/xp9K50QapHF

Excellent work by Shirlyn Wang in print! Exciting team science effort w/ Trachette Jackson Pearson Lab constructing a mathematical model (ODE) to better understand T cell-tumor cell killing dynamics through virtual experiments.
pubmed.ncbi.nlm.nih.gov/38110479/

Fully funded postdoctoral scholar positions are now open in our lab in Chicago.

We study multiple domains of resistance to cancer immunotherapies with a goal of translating findings to new treatments for patients.

sweislab.org

linkedin.com/hiring/jobs/37…